SINGAPORE, Nov. 3, 2026 /PRNewswire/ -- Laboratoires Pierre Fabre Singapore is delighted to announce the access for patients to BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for ...

Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer.

Explore sessions from JADPRO Live 2026 on non-small cell lung cancer, including next-generation sequencing, adverse effect management, and oligometastatic disease evaluation.

A retrospective single-center analysis of 452 Chinese patients with non-small cell lung cancer associated compound and ...

Please provide your email address to receive an email when new articles are posted on . Zongertinib conferred benefits in PFS and response as a first-line treatment option for HER2-mutant advanced non ...

ArriVent’s disappointing data comes just weeks after J&J had a successful readout in the same NSCLC patient population.

Your treatment journey for non-small-cell lung cancer (NSCLC) may vary from that of others with the same diagnosis. But you’ll likely start with some of the same treatments. You’ll have lots of ...

The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who ...

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer. Xiuning Le, MD, PhD, an associate ...